Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model

Neuropharmacology

Volumn 101, Issue , 2016, Pages 255-263

  Li, Yanwei ^a,c   Liu, WeiZhen ^a   Li, Lin ^a   Hölscher, Christian ^a,b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c Shaoyang Medical College   (China)

Author keywords

Apoptosis; Diabetes; Glucose dependent insulinotropic polypeptide; Growth factors; Insulin; Neuroinflammation; Neuroprotection

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BRADYKINESIA; CELL ACTIVATION; CELL SURVIVAL; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MICROGLIA; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; ANALYSIS OF VARIANCE; ANIMAL; BODY EQUILIBRIUM; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MPTP POISONING;

ANALYSIS OF VARIANCE; ANIMALS; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MPTP POISONING; NEUROPROTECTIVE AGENTS; POSTURAL BALANCE; TYROSINE 3-MONOOXYGENASE;

EID: 84944270712     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.10.002     Document Type: Article

References (67)

1. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, T. Soderlund, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, and T. Foltynie Exenatide and the treatment of patients with Parkinson's disease J. Clin. Invest. 123 2013 2730 2736
2. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, J. Kahan, P.E. Fmedsci, P. Whitton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, and T. Foltynie Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease J. Park. Dis. 4 2014 337 344
3. I. Aviles-Olmos, P. Limousin, A. Lees, and T. Foltynie Parkinson's disease, insulin resistance and novel agents of neuroprotection Brain 136 2013 374 384
4. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
5. J. Bove, and C. Perier Neurotoxin-based models of Parkinson's disease Neuroscience 211 2012 51 76
6. B.A. Buhren, M. Gasis, B. Thorens, H.W. Muller, and F. Bosse Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth J. Neurosci. Res. 87 2009 1858 1870
7. E. Cereda, M. Barichella, C. Pedrolli, C. Klersy, E. Cassani, R. Caccialanza, and G. Pezzoli Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis Diabetes Care 34 2011 2614 2623
8. H. Chen, E.J. O'Reilly, M.A. Schwarzschild, and A. Ascherio Peripheral inflammatory biomarkers and risk of Parkinson's disease Am. J. Epidemiol. 167 2008 90 95
9. A.M. Duffy, and C. Holscher The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease Neuroscience 228 2013 294 300
10. E. Faivre, A. Hamilton, and C. Holscher Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice Eur. J. Pharmacol. 674 2012 294 306
11. E. Faivre, and C. Holscher D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model J. Alzheimers Dis. 35 2013 267 283
12. E. Faivre, and C. Holscher Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model Alzheimers Res. Ther. 5 2013 20 28
13. C.C. Ferrari, and R. Tarelli Parkinson's disease and systemic inflammation Park. Dis. 2011 2011 436813
14. C.P. Figueiredo, F.A. Pamplona, T.L. Mazzuco, A.S. Aguiar Jr., R. Walz, and R.D. Prediger Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases Behav. Pharmacol. 21 2010 394 408
15. V.A. Gault, and C. Holscher Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid J. Neurophysiol. 99 2008 1590 1595
16. M. Gerlach, P. Riederer, H. Przuntek, and M.B. Youdim MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease Eur. J. Pharmacol. 208 1991 273 286
17. J.C. Giugni, and M.S. Okun Treatment of advanced Parkinson's disease Curr. Opin. Neurol. 27 2014 450 460
18. V. Glover, C. Gibb, and M. Sandler The role of MAO in MPTP toxicity-a review J. Neural Transm. Suppl. 20 1986 65 76
19. A. Harkavyi, A. Abuirmeileh, R. Lever, A.E. Kingsbury, C.S. Biggs, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J. Neuroinflamm. 5 19 2008 11 19
20. C. Henchcliffe, and M.F. Beal Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nat. Clin. Pract. Neurol. 4 2008 600 609
21. C. Holscher The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease Alzheimers Dement. 10 2014 S47 S54
22. C. Holscher Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases Biochem. Soc. Trans. 42 2014 593 599
23. G. Hu, P. Jousilahti, S. Bidel, R. Antikainen, and J. Tuomilehto Type 2 diabetes and the risk of Parkinson's disease Diabet. Care 30 2007 842 847
24. M.A. Hussain, D.L. Porras, M.H. Rowe, J.R. West, W.J. Song, W.E. Schreiber, and F.E. Wondisford Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation Mol. Cell. Biol. 26 2006 7747 7759
25. N. Irwin, G.C. Clarke, B.D. Green, B. Greer, P. Harriott, V.A. Gault, F.P. O'Harte, and P.R. Flatt Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide Biochem. Pharmacol. 72 2006 719 728
26. N. Irwin, F.P. O'Harte, V.A. Gault, B.D. Green, B. Greer, P. Harriott, C.J. Bailey, and P.R. Flatt GIP(Lys(16)PAL) and GIP(Lys(37)PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential J. Med. Chem. 49 2006 1047 1054
27. D. Jain, R. Jain, D. Eberhard, J. Eglinger, M. Bugliani, L. Piemonti, P. Marchetti, and E. Lammert Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes J. Mol. Cell. Biol. 4 2012 221 230
28. T. Kano, Y. Suzuki, M. Shibuya, K. Kiuchi, and M. Hagiwara Cocaine-induced CREB phosphorylation and c-Fos expression are suppressed in Parkinsonism model mice Neuroreport 6 1995 2197 2200
29. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
30. S. Kim, M. Moon, and S. Park Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease J. Endocrinol. 202 2009 431 439
31. S.J. Kim, C. Nian, and C.H. McIntosh GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene J. Lipid Res. 51 2010 3145 3157
32. S.J. Kim, C. Nian, S. Widenmaier, and C.H. McIntosh Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2 Mol. Cell. Biol. 28 2008 1644 1656
33. S.J. Kim, K. Winter, C. Nian, M. Tsuneoka, Y. Koda, and C.H. McIntosh Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression J. Biol. Chem. 280 2005 22297 22307
34. H. Kinemuchi, C.J. Fowler, and K.F. Tipton The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease Neurochem. Int. 11 1987 359 373
35. I.J. Kopin, and S.P. Markey MPTP toxicity: implications for research in Parkinson's disease Annu. Rev. Neurosci. 11 1988 81 96
36. S.L. Kowal, T.M. Dall, R. Chakrabarti, M.V. Storm, and A. Jain The current and projected economic burden of Parkinson's disease in the United States Mov. Disord. 28 2013 311 318
37. J.W. Langston, L.S. Forno, J. Tetrud, A.G. Reeves, J.A. Kaplan, and D. Karluk Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Ann. Neurol. 46 1999 598 605
38. Y. Li, T. Perry, M.S. Kindy, B.K. Harvey, D. Tweedie, H.W. Holloway, K. Powers, H. Shen, J.M. Egan, K. Sambamurti, A. Brossi, D.K. Lahiri, M.P. Mattson, B.J. Hoffer, Y. Wang, and N.H. Greig GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism Proc. Natl. Acad. Sci. U. S. A. 106 2009 1285 1290
39. Y. Li, D. Tweedie, M.P. Mattson, H.W. Holloway, and N.H. Greig Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells J. Neurochem. 113 2010 1621 1631
40. M.M. Lima, A.D. Targa, A.C. Noseda, L.S. Rodrigues, A.M. Delattre, F.V. dos Santos, M.H. Fortes, M.J. Maturana, and A.C. Ferraz Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments? CNS Neurol. Disord. Drug Targ. 13 2014 418 428
41. R. Lupi, S. Del Guerra, V. D'Aleo, U. Boggi, F. Filipponi, and P. Marchetti The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets Regul. Pept. 165 2010 129 132
42. B. Maino, M.T. Ciotti, P. Calissano, and S. Cavallaro Transcriptional analysis of apoptotic cerebellar granule neurons following rescue by gastric inhibitory polypeptide Int. J. Mol. Sci. 15 2014 5596 5622
43. C.M. Martin, N. Irwin, P.R. Flatt, and V.A. Gault A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores Biochim. Biophys. Acta 1830 2013 3407 3413
44. Y. Miyake, K. Tanaka, W. Fukushima, S. Sasaki, C. Kiyohara, Y. Tsuboi, T. Yamada, T. Oeda, T. Miki, N. Kawamura, N. Sakae, H. Fukuyama, Y. Hirota, M. Nagai, and Fukuoka Kinki Parkinson's Disease StudyGroup Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan J. Neurol. Sci. 293 2010 82 86
45. L.B. Moran, and M.B. Graeber Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation Neurogenetics 9 2008 1 13
46. N. Morin, V.A. Jourdain, and T. Di Paolo Modeling dyskinesia in animal models of Parkinson disease Exp. Neurol. 256 2014 105 116
47. S. Nakamura, and S.R. Vincent Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+ Neurosci. Lett. 65 1986 321 325
48. J. Nyberg, M.F. Anderson, B. Meister, A.M. Alborn, A.K. Strom, A. Brederlau, A.C. Illerskog, O. Nilsson, T.J. Kieffer, M.A. Hietala, A. Ricksten, and P.S. Eriksson Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation J. Neurosci. 25 2005 1816 1825
49. J. Nyberg, C. Jacobsson, M.F. Anderson, and P.S. Eriksson Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain J. Neurosci. Res. 85 2007 2099 2119
50. S. Paratore, M.T. Ciotti, M. Basille, D. Vaudry, A. Gentile, R. Parenti, P. Calissano, and S. Cavallaro Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival Cent. Nerv. Syst. Agents Med. Chem. 11 2011 210 222
51. G. Park, Y.J. Park, H.O. Yang, and M.S. Oh Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism Pharmacol. Biochem. Behav. 104 2013 163 168
52. S.P. Patil, P.D. Jain, P.J. Ghumatkar, R. Tambe, and S. Sathaye Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice Neuroscience 277 2014 747 754
53. G. Paxinos, X. Huang, and A. Toga The Rat Brain in Stereotaxic Coordinates 1999 Academic Press San Diego
54. D.W. Porter, N. Irwin, P.R. Flatt, C. Holscher, and V.A. Gault Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice Eur. J. Pharmacol. 650 2011 688 693
55. A. Pradhan Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders Nutr. Rev. 65 2007 S152 S156
56. D. Rial, A.A. Castro, N. Machado, P. Garcao, F.Q. Goncalves, H.B. Silva, A.R. Tome, A. Kofalvi, O. Corti, R. Raisman-Vozari, R.A. Cunha, and R.D. Prediger Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease PLoS One 9 2014 e114216
57. F. Sa, L.Q. Zhang, C.M. Chong, B.J. Guo, S. Li, Z.J. Zhang, Y. Zheng, P.M. Hoi, and S.M. Lee Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo Neurosci. Lett. 593 2015 7 12
58. J.A. Santiago, and J.A. Potashkin Shared dysregulated pathways lead to Parkinson's disease and diabetes Trends Mol. Med. 19 2013 176 186
59. E. Schernhammer, J. Hansen, K. Rugbjerg, L. Wermuth, and B. Ritz Diabetes and the risk of developing Parkinson's disease in Denmark Diabet. Care 34 2011 1102 1108
60. N. Schintu, L. Frau, M. Ibba, P. Caboni, A. Garau, E. Carboni, and A.R. Carta PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease Eur. J. Neurosci. 29 2009 954 963
61. J.B. Schulz Anti-apoptotic gene therapy in Parkinson's disease J. Neural Transm. Suppl. 2006 467 476
62. M. Sharma, J. Jalewa, and C. Holscher Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress J. Neurochem. 128 2013 459 471
63. S. Sharma, S. Singh, V. Sharma, V.P. Singh, and R. Deshmukh Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies Biomed. Pharmacother. 70 2015 283 293
64. T.S. Smith, and J.P. Bennett Jr. Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions Brain Res. 765 1997 183 188
65. M.G. Tansey, and M.S. Goldberg Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention Neurobiol. Dis. 37 2010 510 518
66. K. Tatarkiewicz, D.M. Hargrove, C.M. Jodka, B.R. Gedulin, P.A. Smith, J.A. Hoyt, A. Lwin, L. Collins, L. Mamedova, O.E. Levy, L. D'Souza, S. Janssen, V. Srivastava, S.S. Ghosh, and D.G. Parkes A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents Diabet. Obes. Metab. 16 2014 75 85
67. G. Xiromerisiou, G.M. Hadjigeorgiou, A. Papadimitriou, E. Katsarogiannis, V. Gourbali, and A.B. Singleton Association between AKT1 gene and Parkinson's disease: a protective haplotype Neurosci. Lett. 436 2008 232 234